Skip to content

Released Nov 6, 2013, after the close

10-Q filed Nov 6, 2013, 37 days after period end · 0001390478-13-000031

Q3 2013 · 10-Q
Revenue$2.17M±0.0% vs Q3 2012−36.0% vs Q2 2013
Net Income-$6.93MN/M vs Q3 2012N/M vs Q2 2013
EPS Diluted-$0.11N/M vs Q3 2012N/M vs Q2 2013
Gross Profit$1,454,000±0.0%
Operating Income-$6,893,000N/M
Operating Cash Flowderived-$7,983,000N/M
Free Cash Flowderived-$8,087,000—
Margins · derived
Gross margin67.1%±0.0 pt vs Q3 2012
Operating margin-318.2%−63.0 pt vs Q3 2012
Net margin-319.9%+512.3 pt vs Q3 2012

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2013Q3 2012Q3 2011Q3 2010
Revenue$2.17M$2.17M——
Net Income-$6.93M-$18.03M-$5.48M-$4.14M
EPS Diluted-$0.11-$0.09-$0.14-$0.23

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR